Primary excision (excision alone) of conjunctival carcinoma and melanoma has been associated with high recurrence rates. Further, these failures of local control are associated with loss of vision, loss of the eye and metastatic disease. Dr. Finger has always felt that the first surgery offers the best chance for cure. Two recent reports have supported that theory.

In 2012, Yousef and Finger reported a retrospective study of 101 cases of squamous dysplasia and carcinoma of the conjunctiva and cornea. They found that when AJCC T1 lesions are treated with excision with “Finger-tip” cryotherapy one could achieve 96% local control success. However, larger lesions required more complex strategies including topical chemotherapy “eye drops” for chemoreduction before surgery or after resection as adjuvant therapy. We have been using either Interferon (Intron), mitomycin and 5-FU alone or sequentially as needed. All local recurrences occurred within two years of follow up and only one patient developed metastasis.

We use external beam electron-based radiation therapy for unresponsive conjunctival squamous carcinomas.

Dr. Finger says, “I introduced specialized hand-held “Finger-tip” cryotherapy units, mitomycin eye drops for conjunctival melanoma and interferon eye drops as well. Clearly, I have the experience to know the strengths and limitations of each treatment.

**Take Away Messages:**
1) The first surgery offers the best chance for cure.
2) Larger tumors require more complex multi-modality treatments.
3) Eyes and vision can be salvaged using radiation for if necessary.
Excision and Cryotherapy
The Current Standard

Excision alone has been shown to be an inadequate treatment for both conjunctival melanoma and squamous carcinoma. This finding is because the tumors edges typically extend beyond its visible margins. For example, when you look at a squamous carcinoma extending onto the cornea, there typically is a gray, avascular and fairly translucent advancing edge. It is reasonable to assume the conjunctival margins are also gray, translucent and advancing. But, these margins are much more difficult to see with the white sclera as a backdrop. Similarly, conjunctival melanomas are known to include edges that are not pigmented. Therefore, if you are relying on the pigmented margin of a conjunctival melanoma to be the tumors edge, you are likely wrong.

This is why Dr. Finger typically excises these tumors with 2 mm visible margins and add “Finger-tip” cryotherapy (bottom right figure) to extend the margins an additional 3 mm. This allows for a total of 5 mm. Diffuse and multifocal tumor treatments are more complex.

“Finger-tip” Cryotherapy destroys cells in several ways:

- First, the rapid creation of intracellular ice (within cancer cells) is lethal.
- Second, as ice forms outside a cell, the water inside is drawn out. This shrinks the cell and collapses cellular membranes resulting in a release of proteins and chemicals that kill cancer cells.
- Third, as ice (that surrounds shrunken cells) begins to thaw, large amounts of free water (produced by the thawing ice) rush back inside the cancer cells making them burst.

Modern cryosurgery is performed in a manner to produce a predictable tissue response in the target cancer. Factors that influence the efficacy of cryodestruction include the cooling rate, tissue temperature, the freeze-thaw cycle, and the number of repetitions. Special techniques must be used to prevent or limit intraocular freezing that might affect vision.

Conjunctival Melanoma

Does the AJCC Staging System Predict Local Control and Metastasis?

We evaluated the predictive value of the 7th edition, American Joint Committee on Cancer (AJCC) staging system for conjunctival melanoma.

Forty-two patients were studied. Recurrent disease was noted in 33% with 64% occurring at a median 2.5 (range 1-5) years after primary treatment.

Risk Factors for Recurrence:
- Larger tumor size
- Larger tumor thickness
- Multifocality
- Higher AJCC T-stage

Risk Factor for Metastasis:
- Larger tumor thickness
- Local tumor invasiveness
- Local tumor recurrence
- Higher AJCC T-stage

Histopathologic diagnosis was correlated to recurrence (P = 0.037). For example, none of the tumors defined histologically as dysplasia showed recurrence, whereas 12.8% of carcinoma in situ tumors and 22.2% of squamous cell carcinoma tumors recurred. Although the overall recurrence rate was 12.9%, the rate for tumors treated primarily at The New York Eye Cancer Center was only 4% ([significantly less than the recurrence rate in previously operated tumors (P = 0.0003)].)

Conclusions:
- Advanced AJCC T-stage, locally invasive tumors, and more pathologically aggressive tumors were at higher risk for recurrence.
- Inadequate initial therapy also was an important risk factor for recurrence.
- Treatment strategies should be affected by AJCC tumor staging at presentation.

Conjunctival Tumor Pearls:
- Take an initial photograph of all conjunctival surfaces for staging.
- Palpate for preauricular and cervical lymph nodes.
- If affixed to the globe, evaluate with a high-frequency ultrasound (UBM).
- Incisional biopsy can cause local failure.
- Local failure causes morbidity.
- Other than scraping for cytology, surgery should have curative intent.
About Paul T. Finger, MD

Clinical Professor of Ophthalmology, Dr. Finger is a specialist in ocular tumors, orbital diseases and ophthalmic radiation therapy. He has developed new methods for the diagnosis and treatment of many ocular tumors, holds many patents and has written hundreds of scientific publications.

Dr. Finger is invited to lecture frequently at local, national and international meetings. He is founding Director of The New York Eye Cancer Center and The Ocular Tumor Services of The New York Eye and Ear Infirmary and NYU School of Medicine.

Dr. Finger is the Chair of the (AJCC) American Joint Committee on Cancer's Ophthalmic Oncology Task Force and a member of the Committee on Cancer (COC) of the American College of Surgeons. Further, he consults for The American Brachytherapy Society (ABS) and the Association for Physicists in Medicine (AAPM).

For more information visit his web site: 
http://paultfingermd.com

THE NEW YORK EYE CANCER CENTER
115 EAST 61ST STREET - SUITE 5B
NEW YORK CITY, NEW YORK,
USA 10065
Tel: 212-832-8170
PFINGER@EYECANCER.COM

http://paultfingermd.com
http://eyecancer.com

Name: 
Address: 
State, City, Zip: